Meet the editor

Ota Fuchs graduated from the Chemical Technological University, Prague, Czech Republic, in 1971. He obtained his Ph.D. in Biochemistry from the Faculty of Natural Sciences, Charles University, Prague, in 1981. He is employed as a Senior Scientist at the Institute of Hematology and Blood Transfusion, Prague. He undertook as visiting scientist short-term affiliations at the Beatson Institute for Cancer Research, Glasgow, UK; Insti-

tute of Experimental Medicine of the Russian Academy of Medical Sciences in St Peterburg, Russia; and Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Canada. Dr. Fuchs was the principal investigator of five projects of the Internal Grant Agency of the Ministry of Health of the Czech Republic and one grant project of the Grant Agency of Czech Republic.

Contents

*by Ota Fuchs*

Overall Survival

*by Howard R. Terebelo and Leo Reap*

Treatment Approaches of Multiple Myeloma

Antibody Therapies for Multiple Myeloma

an Effective Treatment? A Case Report

**Preface XI**

**Chapter 1 1** Introductory Chapter: Oral Selinexor, a Selective Inhibitor of Nuclear Export in the Treatment of Patients with Multiple Myeloma Refractory to Proteasome

**Chapter 2 9**

**Chapter 3 27**

**Chapter 4 45**

**Chapter 5 67** The Modern Age of Monoclonal Antibodies: The Revolution of Daratumumab

**Chapter 6 83**

**Chapter 7 93** 3D Models of Surrogate Multiple Myeloma Bone Marrow Microenvironments: Insights on Disease Pathophysiology and Patient-Specific Response to Drugs *by Marina Ferrarini, Magda Marcatti, Fabio Ciceri and Elisabetta Ferrero*

Inhibitors, Immunomodulatory Agents and Monoclonal Antibodies

Prognostic and Predictive Factors in Newly Diagnosed Multiple Myeloma Patients with Early Mortality with Prediction Matrix and Three and Five-Year

*by Minyahil Alebachew Woldu, Atalay Mulu Fentie and Tamrat Assefa Tadesse*

*by Nikolaos Kanellias, Maria Gavriatopoulou and Evangelos Terpos*

*by Gianfranco Lapietra, Francesca Fazio and Maria Teresa Petrucci*

Pleural Effusion Secondary to Multiple Myeloma: Is Daratumumab

*by Giulia Palazzo, Lara Aprile, Giacomo Cecere, Vito Pier Gagliardi, Alessandro Maggi, Antonella Prudenzano and Patrizio Mazza*
